Indoco Remedies Clinical Research Organisation AnaCipher gets UKMHRA Accreditation
Published On 28 Aug 2021 11:30 AM | Updated On 28 Aug 2021 6:52 PM
![](images/Indoco-house1.jpg)
Mumbai: Indoco Remedies Ltd. has recently announced the receipt of GCP & GLP
accreditation from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Organisation - AnaCipher, located at Hyderabad
for the virtual inspection carried out from 4th – 7th May and 10th - 11th May, 2021.
The inspection covered all the phases of Bioequivalence studies and was conducted
successfully.
"This is an exciting step in our journey of excellence and a validation of our
adherence to delivering quality services to our customers worldwide.", stated Ms. Aditi Kare Panandikar, Managing Director,
Indoco Remedies Limited.
AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research
facility and is spread over 30,000 sq. ft area with 98 beds and staffed by experienced professionals providing
clinical trial solutions and conducts Bioequivalence and Bioavailability (BA/BE) studies at its facility.
The CRO has successfully completed more than 500 studies in multiple therapeutic areas such as, cardiovascular, diabetes,
oncology, anti-retrovirals and antacids.
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research oriented pharma
company with presence in 55 countries Indoco has 9 domestic marketing divisions with a strong brand portfolio in various
therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional,
Cardiovascular, Anti-Diabetics, Pain Management, etc. Top Indoco brands include Cyclopam, Febrex Plus, SensodentK,
Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM,
Methycal, etc
|